Transgene's viral cancer vaccine flunks midphase test—but subgroup signal spurs ongoing analysis

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to improve progression-free survival (PFS), the French biotech is continuing to analyze aspects of the data including a “positive efficacy trend” in a prespecified subgroup before deciding on its next steps.